Drug Trial Radar · NCT01293097
Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI
Last checked: Nov 19, 2026Latest source record: Apr 30, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,884
Actual
Start
Jun 2010
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- Peking University First HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 10, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, open label, controlled, parallel group study is designed to test whether 2-day high dose atorvastatin administration before PCI and 30-day continuous intensive atorvastatin treatment is superior to usual care, in terms of peri-PCI cardiovascular events, as well as 6-month prognosis. The goal is to set up an optimized protocol for peri-PCI statin treatment in Chinese CHD patients. Safety will also be observed.
Conditions
- Non-ST Segment Elevation Myocardial Infarction
- Unstable Angina Pectoris
- Stable Angina Pectoris
Interventions
AtorvastatinDrug
Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
StatinDrug
Usual care, but statin dose should not be higher than that described in exclusion criteria
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30-day MACEs after PCITime frame: 30 days after PCI
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Cardiology, Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.